You just read:

Imfinzi® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefits in Unresectable, Stage III Non-Small Cell Lung Cancer

News provided by

AstraZeneca

Sep 25, 2018, 12:58 ET